Research Associate I
1 DNA Way South San Francisco, California 94080 | Contract
Our client is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. They are among the world' s leading biotech companies, with multiple products on the market and a promising development pipeline.
- The department of Translational Oncology in Genentech Research and Early Development is seeking a highly motivated Scientific Researcher/Senior Scientific Researcher to conduct preclinical translational research focusing on hematologic malignancies.
- The candidate will represent the department on cross-functional research and development project teams by designing and implementing in vitro and in vivo studies to assess pharmacodynamics, mechanism of action of new molecular entities or standard of care drugs as single agents or in combination therapies across a spectrum of models representing hematologic malignancies.
- The successful candidate will work and partner closely with other senior scientific researchers, scientific supervisors and scientists within the research discovery and biomarkers groups to identify and address key questions.
- The successful candidate will lead efforts in the following areas of focus:
- Establishing disease relevant, orthotopic models of hematologic malignancies.
- Characterizing and phenotyping genetically engineered mouse models (GEMMs) of hematologic malignancies.
- Evaluating efficacy, pharmacokinetics/pharmacodynamics and mechanism of action of ourpipeline small molecule and immuno-oncology therapies targeting hematologic malignancies using in vitro (cell culture derived), ex vivo (patient derived) and in vivo tumor models.
- Defining drug combinations of standard of care therapeutics with new molecular entities based on strong scientific and mechanistic rationale in vitro and in vivo.
- Elucidating mechanism of action of drug combinations that result in enhanced sensitivity or rescue drug resistance.
- Qualified applicants will have demonstrated experience with in vitro, ex vivo and/or in vivo studies.
- Experience with in vitro techniques focused in biochemical, molecular and cellular biology, including Western blotting; immunoprecipitation; analysis of cell differentiation, proliferation, survival, death and adhesion using standard assay formats (i.e. CellTiter-Glo, Annexin V, Caspase/PARP cleavage); FACS (surface and intracellular staining); establishment and maintenance of stable cell lines through retroviral and/or lentiviral transduction; gene silencing or mutagenesis (siRNA, shRNA, CRISPR); gene expression analysis (qPCR, Fluidigm) and ELISA are ideal.
- Tissue culture experience using established/banked tumor cell lines (i.e. from ATCC or DSMZ) is required.
- Experience with basic rodent husbandry and handling is required.
- In vivo duties will include establishing, monitoring and maintaining xenograft models using sterile in vivo techniques.
- Proficiency in establishing and maintaining patient-derived hematologic tumor samples ex vivo and analysis of pharmacodynamics makers is desired.
- Proven ability to manage multiple projects in parallel and keep up to date documentation is essential.
- A strong desire to proactively learn and implement new in vitro and in vivo techniques and skillsets in accordance with evolving research program needs is essential.
- Strong organizational, problem solving and verbal/written communication skills are required for this role.
- Candidates must be capable of standing, lifting, kneeling, bending, etc., for extended periods of time.
- Must be willing to work with potentially hazardous materials and be able to lift a minimum of 50 pounds.
- A BA/BS in biomedical sciences with greater than 3 years of experience in an academic, biotechnology or pharmaceutical industry laboratory.
- Those who lack industry experience but have a Masters degree or a Doctor of Philosophy degree with thesis research experience in a related field will be considered.
- Expertise and specialization in hematologic malignancies and relevant disease models systems is desired.